✅Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma out on @NEJM  https://www.nejm.org/doi/full/10.1056/NEJMoa2312695#ap0 ✅Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial  https://www.annalsofoncology.org/article/S0923-7534(24)00105-4/fulltext ✅Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(24)00185-X ✅Three-year overall survival outcomes and correlative analyses in patients with non–small-cell lung cancer and high (50-89%) versus very high (≥90%) PD-L1 expression treated with first-line pembrolizumab or cemiplimab https://www.jtocrr.org/article/S2666-3643(24)00045-6/fulltext ✅The Lancet Breast Cancer Commission https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00747-5/fulltext ✅Top advances of the year: Uterine cancer https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.35321